within Pharmacolibrary.Drugs.ATC.L;

model L01DB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.5833333333333334,
    adminDuration  = 600,
    adminMass      = 0.06,
    adminCount     = 1,
    Vd             = 0.025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Doxorubicin is an anthracycline antibiotic that is widely used as a cytotoxic agent in the treatment of various cancers, including breast cancer, lymphomas, leukemias, and sarcomas. It works primarily by intercalating DNA and inhibiting topoisomerase II, resulting in inhibition of DNA replication and apoptosis of cancer cells. Doxorubicin is FDA approved and commonly used today, but its use is limited by its potential for cardiotoxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult cancer patients (both sexes), following intravenous administration of a single dose.</p><h4>References</h4><ol><li><p>Ryu, RJ, et al., &amp; Hebert, MF (2014). Pharmacokinetics of doxorubicin in pregnant women. <i>Cancer chemotherapy and pharmacology</i> 73(4) 789–797. DOI:<a href=&quot;https://doi.org/10.1007/s00280-014-2406-z&quot;>10.1007/s00280-014-2406-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24531558/&quot;>https://pubmed.ncbi.nlm.nih.gov/24531558</a></p></li><li><p>He, P, et al., &amp; Hu, Y (2022). Pharmacodynamics and pharmacokinetics of PLGA-based doxorubicin-loaded implants for tumor therapy. <i>Drug delivery</i> 29(1) 478–488. DOI:<a href=&quot;https://doi.org/10.1080/10717544.2022.2032878&quot;>10.1080/10717544.2022.2032878</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35147071/&quot;>https://pubmed.ncbi.nlm.nih.gov/35147071</a></p></li><li><p>Johansen, PB (1981). Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. <i>Cancer chemotherapy and pharmacology</i> 5(4) 267–270. DOI:<a href=&quot;https://doi.org/10.1007/BF00434396&quot;>10.1007/BF00434396</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7261254/&quot;>https://pubmed.ncbi.nlm.nih.gov/7261254</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01DB01;
